LLY
Eli Lilly and Company
LLY has the edge over ORGO overall, supported by stronger fundamentals and lower modeled downside.
ORGO
Organogenesis Holdings Inc.
ORGO trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ORGO Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Under pressure | |
| Strong |
ORGO's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ORGO PE Valuation
ORGO has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over ORGO on the outlook, with more favorable revenue and profitability expectations.
ORGO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect ORGO's losses to shrink, with revenue declining.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ORGO on earnings quality, reporting a profit while its opponent remains loss making.
ORGO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.15 | -$1.04 |
| Q2 2026 | -$0.79 | -$0.66 |
| Q1 2026 | -$0.12 | +$0.04 |
| Q4 2025 | $0.15 | +$0.16 |
| Q3 2025 | -$0.11 | -$0.05 |
| Q2 2025 | -$0.13 | $0.00 |
| Q1 2025 | -$0.16 | -500% |
| Q4 2024 | -$0.01 | -125% |
ORGO lost $1.15 per share over the past year, and its loss has widened in each of the last three quarters.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ORGO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ORGO on profitability, with a higher operating margin.
ORGO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $45.5M | -70% |
| Q2 2026 | $43.8M | -57% |
| Q1 2026 | $37.2M | -57% |
| Q4 2025 | $225.6M | +78% |
| Q3 2025 | $150.9M | +31% |
| Q2 2025 | $101M | -22% |
| Q1 2025 | $86.7M | -21% |
| Q4 2024 | $126.7M | +27% |
ORGO's revenue is shrinking: $45M last quarter, down 70% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -65% | -79 points |
| Q2 2026 | -117% | -104 points |
| Q1 2026 | -185% | -154 points |
| Q4 2025 | 28% | +20 points |
| Q3 2025 | 14% | +8.3 points |
| Q2 2025 | -12% | -1.8 points |
| Q1 2025 | -31% | -27 points |
| Q4 2024 | 8.1% | +9.3 points |
ORGO's operating margin was −65% last quarter, down 79 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ORGO on cash generation, producing positive trailing cash flow while its opponent burns cash.
ORGO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$20.1M | -2477% |
| Q2 2026 | -$32.8M | +$3.8M |
| Q1 2026 | $18M | +$41.5M |
| Q4 2025 | $34.8M | +359% |
| Q3 2025 | $844K | -86% |
| Q2 2025 | -$36.5M | -1378% |
| Q1 2025 | -$23.6M | -$11.2M |
| Q4 2024 | $7.6M | +3.9% |
ORGO's free cash flow was −$64,000 over the past year, against −$52M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ORGO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +316K shares |
| 1 year | -1.4% | -1.9M shares |
| 3 years | -3.3% | -4.4M shares |
| 5 years | -3.6% | -4.9M shares |
| Available history | +39% | +36.2M shares |
ORGO has the edge over LLY on shareholder dilution, with a more favorable share count trend.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ORGO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -4.9x | Net Cash |
| Q4 2025 | -1.6x | Net Cash |
| Q3 2025 | -9.9x | Net Cash |
| Q4 2024 | -10.2x | Net Cash |
| Q3 2024 | -13.6x | Net Cash |
| Q2 2024 | -6.0x | Net Cash |
| Q1 2024 | -0.8x | Net Cash |
| Q4 2023 | -1.3x | Net Cash |
ORGO has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ORGO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.3 | Oversold |
| Stochastic | 7.8 | Oversold |
ORGO's weekly RSI is 27 (oversold) and its Stochastic is 8 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ORGO PE vs Healthcare Sector
| Metric | ORGO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ORGO has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ORGO on trend strength, trading above more of its moving averages.
ORGO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.07 | 10% below |
| 20 week MA | $1.63 | 41% below |
| 50 week MA | $2.60 | 63% below |
| 100 week MA | $3.40 | 72% below |
| 200 week MA | $3.18 | 70% below |
ORGO is in a downtrend: it's below all five of its weekly moving averages, and 70% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ORGO on returns for 2026, with the stronger performance.
ORGO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.94 | $6.46 | +31% |
| 2021 | $6.46 | $10.2 | +58% |
| 2022 | $10.2 | $2.59 | -75% |
| 2023 | $2.59 | $4.09 | +58% |
| 2024 | $4.09 | $3.19 | -22% |
| 2025 | $3.19 | $5.28 | +66% |
| 2026 YTD | $5.28 | $0.96 | -82% |
ORGO is down 82% so far in 2026, after finishing higher in four of the previous six years.